

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 November 2008 (06.11.2008)

PCT

(10) International Publication Number
WO 2008/132224 A2

(51) International Patent Classification:
A61K 9/16 (2006.01) A61K 38/28 (2006.01)

(21) International Application Number:
PCT/EP2008/055306

(22) International Filing Date: 30 April 2008 (30.04.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
07107221.9 30 April 2007 (30.04.2007) EP
07117798.4 3 October 2007 (03.10.2007) EP

(71) Applicant (for all designated States except US): **NOVO NORDISK A/S** [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HAVELUND, Svend** [DK/DK]; Kurvej 24, DK-2880 Bagsvaerd (DK). **JENSEN, Simon, Bjerregaard** [DK/DK]; Ved Skelbækken 7, DK-3400 Hillerød (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report



WO 2008/132224 A2

(54) Title: METHOD FOR DRYING A PROTEIN COMPOSITION, A DRIED PROTEIN COMPOSITION AND A PHARMACEUTICAL COMPOSITION COMPRISING THE DRIED PROTEIN

(57) Abstract: The present invention relates to a method for spray-drying of protein solutions and the spray-dried protein product. The invention also relates to pharmaceutical compositions containing such spray-dried protein, to methods of treating diabetes and hyperglycaemia using the spray-dried protein of the invention and to the use of such spray-dried protein in the treatment of diabetes and hyperglycaemia.

METHOD FOR DRYING A PROTEIN COMPOSITION, A DRIED PROTEIN COMPOSITION AND A PHARMACEUTICAL COMPOSITION COMPRISING THE DRIED PROTEIN.

FIELD OF THE INVENTION

5 The present invention relates to a method for drying of protein solutions and the dried protein product. The invention also relates to pharmaceutical compositions containing such dried protein, to methods of treating diabetes and hyperglycaemia using the dried protein of the invention and to the use of such dried protein in the treatment of diabetes and hyperglycaemia.

BACKGROUND OF THE INVENTION

10 Drying is a mass transfer process resulting in the removal of water moisture by evaporation from a solid, semi-solid or liquid to end in a solid state. A possible drying method is vacuum drying, where heat is supplied by contact conduction or radiation (or microwaves) while the produced vapor is removed by the vacuum system. Another technique is drum drying, where a heated surface is used to provide the energy and aspirators draw the vapor outside the room.

15 Freeze drying or lyophilization is a drying method commonly used in the biochemical industry. The solvent is frozen prior to drying and is then sublimed, i.e., passed to the gas phase directly from the solid phase, below the melting point of the solvent. Freeze drying is often carried out under high vacuum to allow drying to proceed at a reasonable rate.

20 Denaturation of protein and peptides can occur during freezing, leading to a freeze dried product with poor quality. Spray drying has a wide range of application within the chemical industry, the food industry, and the biochemical and pharmaceutical industries. Spray drying has been used in the pharmaceutical industry since the early 1940's. It is a useful method for the processing of pharmaceuticals since it offers a means for obtaining powders with predetermined properties, such as particle size distribution and shape. In addition a number of formulation processes can be accomplished in one step in a spray dryer: these include encapsulation, complex formation and even polymerizations. Spray drying is also a convenient method of drying heat sensitive pharmaceuticals, such as protein drugs with minimal loss of activity.

25 The international patent application WO 00/00176 disclose a microparticle formulation obtainable by spray-drying a substantially pure solution of a therapeutic agent without the concomitant production of an undesirable high concentration of salt or other excipients. Salt is said to be undesirable because it has no stabilising effect, indeed the stability may be

30

greater with reduced amounts of salt. Insulin microparticles are obtainable by dissolving Zn-insulin in acid (HCl), adding alkali (NaOH) to give an insulin solution, e.g. to a pH above 7, and spray-drying the insulin solution. The added Hydrochloric acid and Sodium hydroxide leaves the spray-dried microparticle formulation with a salt content. Further the obtained
5 formulation will on addition to water have the same pH as the protein solution fed in the spray-dryer.

International patent publication WO 95/24183 relates to methods and compositions for pulmonary delivery of insulin. The insulin powders are produced by mixing bulk crystalline insulin in a sodium citrate buffer containing excipients (mannitol and/or raffinose) to give final
10 solids concentration of 7.5 mg/ml and a pH of 6.7 ± 0.3 and then spray-drying the insulin solution.

International patent publication WO 05/092301 relates to spray drying a clear solution of insulin at pH under the isoelectric point of insulin, preferably lower than 5.4.

Human GLP-1 is a 37 amino acid residue peptide originating from preproglucagon which is
15 synthesized *i.a.* in the L-cells in the distal ileum, in the pancreas and in the brain. GLP-1 is an important gut hormone with regulatory function in glucose metabolism and gastrointestinal secretion and metabolism. GLP-1 stimulates insulin secretion in a glucose-dependant manner, stimulates insulin biosynthesis, promotes beta cell rescue, decreases glucagon secretion, gastric emptying and food intake. Human GLP-1 is hydrolysed to GLP-1(7-37) and GLP-
20 1(7-36)-amide which are both insulinotropic peptides.

The therapeutic hormone insulin is a small protein having influence on the blood glucose level. It is daily used in the medical treatment of diabetes by millions of people. Diabetes is a chronic disease caused by absolute or relative deficiency of insulin and insulin resistance, which results in high blood glucose levels (hyperglycemia) leading to long-term
25 complications.

Currently, the treatment of diabetes, both type 1 diabetes and type 2 diabetes, relies to an increasing extent on the so-called intensive insulin treatment. According to this regimen, the patients are treated with multiple daily insulin injections comprising one or two daily injections of long acting insulin to cover the basal insulin requirement supplemented by bolus injections of
30 rapid acting insulin to cover the insulin requirement related to meals.

The molecule of insulin consists of two chains, A and B, with 21 and 30 residues respectively. The A chain is built up by two helical fragments separated by a short elongated part linked to one of the helices by an intra-chain disulfide bond. Two additional disulfide bonds link the A chain to the larger B chain. In the biologically active form insulin exists as a
35 monomer in which the B chain contains a central helical region flanked by two elongated

parts. In the presence of divalent ions like zinc, the monomers assemble into hexamers, where each of the two central zinc ions is coordinated by three histidine residues.

Insulin is susceptible to fibrillation, a misfolding process leading to well ordered cross- β assembly. Protection from fibrillation in β cells is provided by sequestration of the susceptible monomer within zinc hexamers. When fibrillation occurs during the spray-drying of insulin, the nozzle may clog, leading to interruptions in the drying process.

Another important factor when avoiding clogging of the spray-drying nozzles is that the protein to be dried is properly dissolved in the solution. Protein dispersed in the feed solution may also lead to clogging of the equipment.

Further the pH of the dried protein is very important. It is often desirable to obtain a dried product with a specified pH, eg. a pH comparable to physiological pH.

SUMMARY OF THE INVENTION

The present invention concerns a process for drying a protein solution, wherein

- a) A protein solution is obtained by mixing a protein with water optionally comprising excipients and adjusting the pH with a volatile base, a non volatile base and optionally a non volatile acid for the protein solution to become alkaline, and
- b) Drying the protein solution

Additionally the invention concerns a dried protein obtainable by the mentioned process, a pharmaceutical composition comprising the dried protein and a method for treating diabetes.

DEFINITIONS

A “**protein solution**” as mentioned herein means a solution of insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues, GLP-1 derivatives or glucagon which has been solubilised without the use of acids and at pH values above the isoelectric point of the protein.

By “**volatile base**” is meant a base, which to some extent will evaporate upon heating and/or at reduced pressure, e.g. bases which have a vapour pressure above 65 Pa at room temperature or an aqueous azeotropic mixture including a base having a vapour pressure above 65 Pa at room temperature .

A “**non volatile base**” as mentioned herein means a base, which do not evaporate or only partly evaporate upon heating, e.g. bases with a vapour pressure below 65 Pa at room temperature.

A "**non volatile acid**" as mentioned herein means an acid, which do not evaporate or only partly evaporate upon heating, e.g. acids with a vapour pressure below 65 Pa at room temperature such as phosphoric acid.

5 A "**strong acid**" as mentioned herein means an acid, which have a pKa value below -1 such as hydrochloric acid and sulphuric acid.

With "**insulin**" as used herein is meant human insulin, porcine insulin or bovine insulin with disulfide bridges between CysA7 and CysB7 and between CysA20 and CysB19 and an internal disulfide bridge between CysA6 and CysA11 or an insulin analogue or derivative thereof.

10 With "**GLP-1**" as used herein is meant glucagon-like peptide-1. Human GLP-1 is a 37 amino acid residue peptide. Human GLP-1 is hydrolysed to GLP-1(7-37) and GLP-1(7-36)-amide which are both insulinotropic peptides.

By "**pH of the protein solution/insulin solution/GLP-1 solution/glucagon solution**" is meant the pH of the protein/insulin/GLP-1/glucagon solution after adjustment with volatile and non volatile bases and before spray drying of the protein solution.

15 By "**pH of the dried protein/insulin/GLP-1/glucagon**" is meant the pH of the dried/spray-dried protein/insulin/GLP-1/glucagon when mixing at least 20 mg spray dried/dried protein with 0.5 ml demineralised water, giving a concentration of at least 40 mg protein/insulin/GLP-1 per ml of demineralised water, and measuring pH. The pH of the dried protein/insulin/GLP-1 can be measured by mixing up to about 300 mg spray dried/dried protein/insulin/GLP-1 with 0.5 ml demineralised water and measuring the pH. For example the pH is measure by mixing about 20 to about 250 mg spray dried/dried protein/insulin/GLP-1/glucagon with 0.5 ml demineralised water, by mixing about 20 to about 200 mg spray dried/dried protein/insulin/GLP-1/glucagon with 0.5 ml demineralised water, by mixing about 20 to about 150 mg spray dried/dried protein/insulin/GLP-1/glucagon with 0.5 ml demineralised water or by mixing about 20 to about 100 mg spray dried/dried protein/insulin/GLP-1/glucagon with 0.5 ml demineralised water and measuring pH.

25 By "**target pH for the dried protein**" is meant the pH for the dried protein/insulin/GLP-1/ glucagon that are desirable to achieve for the dried protein, eg. the pH where the chemical stability of the dried protein is optimal or the pH of the dried protein is comparable to physiological pH.

30 By "**target pH for the protein solution**" is meant the pH that would be desirable for the protein solution/insulin solution/GLP-1 solution/glucagon solution when it should be dried, eg. the pH are at the optimum for the dissolved protein due to high solubility or low aggregation potential.

35

By "**analogue**" as used herein is meant a polypeptide which has a molecular structure which formally can be derived from the structure of the protein, by deleting and/or exchanging at least one amino acid residue occurring in the naturally occurring protein and/or adding at least one amino acid residue. The added and/or exchanged amino acid residues can either be cod-
5 able amino acid residues or other naturally occurring residues or purely synthetic amino acid residues. The insulin analogues may be such wherein position 28 of the B chain may be modified from the natural Pro residue to one of Asp, Lys, or Ile. In another aspect Lys at position B29 of insulin is modified to Pro or Glu. Also, Asn at position A21 may be modified to
10 Ala, Gln, Glu, Gly, His, Ile, Leu, Met, Ser, Thr, Trp, Tyr or Val, in particular to Gly, Ala, Ser, or Thr and preferably to Gly. Furthermore, Asn at position B3 may be modified to Lys, Thr, Ser, Gln, Glu or Asp. Further examples of insulin analogues are des(B30) human insulin; des(B30) human insulin analogues; insulin analogues wherein PheB1 has been deleted; insulin analogues wherein the A-chain and/or the B-chain have an N-terminal extension and insulin analogues wherein the A-chain and/or the B-chain have a C-terminal extension. Thus
15 one or two Arg may be added to position B1.

A simple system is used to describe analogues of the GLP-1 peptide. Thus, for example, [Gly⁸]GLP-1(7-37) designates an analogue of GLP-1(7-37) formally derived from GLP-1(7-37) by substituting the naturally occurring amino acid residue in position 8 (Ala) by Gly. The GLP-1 analogues may be such wherein the naturally occurring Lys at position 34 of
20 GLP-1(7-37) has been substituted with Arg. All amino acids for which the optical isomer is not stated is to be understood to mean the L-isomer.

In aspects of the invention a maximum of 17 amino acids have been modified. In aspects of the invention a maximum of 15 amino acids have been modified. In aspects of the invention a maximum of 10 amino acids have been modified. In aspects of the invention a maximum of
25 8 amino acids have been modified. In aspects of the invention a maximum of 7 amino acids have been modified. In aspects of the invention a maximum of 6 amino acids have been modified. In aspects of the invention a maximum of 5 amino acids have been modified. In aspects of the invention a maximum of 4 amino acids have been modified. In aspects of the invention a maximum of 3 amino acids have been modified. In aspects of the invention a
30 maximum of 2 amino acids have been modified. In aspects of the invention 1 amino acid has been modified.

With "**desB30 insulin**", "**desB30 human insulin**" is meant insulin or an analogue thereof lacking the B30 amino acid residue.

By "**parent insulin**" is meant a naturally occurring insulin such as human insulin or
35 porcine insulin. Alternatively, the parent insulin can be an insulin analogue.

By "**derivative**" as used herein is meant a naturally occurring protein or an analogue thereof which has been chemically modified, e.g. by introducing a substituent in one or more positions of the protein backbone or by oxidizing or reducing groups of the amino acid residues in the protein or by acylating a free amino group or a hydroxy group.

5

DESCRIPTION OF THE INVENTION

With the process of the invention it is possible to obtain a dried protein powder with a pH that is different from the pH of the protein solution which are dried.

The present invention concerns process for drying a process for drying a protein solution,
10 wherein

- a) A protein solution is obtained by mixing a protein with water optionally comprising excipients and adjusting the pH with a volatile base, a non volatile base and optionally a non volatile acid for the protein solution to become alkaline, and
- b) Drying the protein solution.

15 In one aspect of the invention the process comprises:

- a) Selecting a target pH for the dried protein,
- b) Selecting a target pH for the protein solution,
- c) Providing an aqueous phase,
- d) Adding a protein,
- 20 e) Optionally adding excipients,
- f) Adjusting the pH with a non volatile base and optionally a non volatile acid to the target pH for the dried protein,
- g) Adjusting the pH with a volatile base to the target pH of the protein solution to be dried, and
- 25 h) Spray-drying the protein solution.

wherein the steps d, e, f and g can be carried out in any order while stirring continuously.

In one aspect of the invention the steps d, e and f can be carried out in any order while stirring continuously.

In one aspect the protein solution is adjusted with a volatile base and a non volatile base.

30 In one aspect the process the protein solution is obtained at a temperature below about 8°C, below about 6°C, below about 5°C, below about 4°C, below about 3°C, below about 2°C or below about 1°C.

In one aspect the freezing point of the water is depressed and protein solution is obtained at a temperature below 0°C.

In one aspect the protein solution has a pH or a target pH above about 7.4, above about 7.6, above about 7.8, above about 8.0, above about 8.2, above about 8.4 or above about 8.6.

The tendency for the proteins to fibrillate is less pronounced when the pH of the protein solution is between about 7.6 and about 11.0, between about 7.6 and about 10.5, between about 7.8 and about 11.0, between about 7.8 and about 10.5, between about 8.0 and about 11.0, between about 8.0 and about 10.5, between about 8.2 and about 11.0, between about 8.4 and about 11.0, between about 8.6 and about 10.0, between about 8.8 and about 10.0, between about 9.0 and about 10.0 or between about 9.2 and about 10.0.

In one aspect of the invention the protein is added to an aqueous solution. The aqueous solution can be pure water or it can contain excipients or an alkaline.

In one aspect of the invention the pH of the protein solution is adjusted with an alkaline solution comprising a non volatile base. The non volatile base can be selected from the group consisting of alkaline metal salts, alkaline metal hydroxides, alkaline earth metal salts, alkaline earth metal hydroxides and amino acids or a combination hereof. For example the pH can be adjusted with sodium hydroxide, potassium hydroxide, calcium hydroxide, calcium oxide or any combination hereof.


In one aspect of the invention the pH of the protein solution is adjusted with an alkaline solution comprising a volatile base. The volatile base can be selected from the group consisting of ammonium hydroxides, tetraalkylammonium hydroxides, secondary amines, tertiary amines, aryl amines, aliphatic amines or ammonium bicarbonate or a combination. For example the volatile base can be bicarbonate, carbonate, ammonia, hydrazine or an organic base such as a lower aliphatic amines e.g. trimethyl amine, triethylamine, diethanolamines, triethanolamine and their salts. Further the volatile base can be ammonium hydroxide, ethyl amine or methyl amine or a combination hereof.

Upon addition of ammonium hydroxide to an aqueous solution containing insulin, the protein, for example insulin will dissolve more rapidly.

In one aspect of the invention the pH of the protein solution is adjusted with an alkaline solution comprising a volatile base and a non volatile base. In one aspect the pH of the protein solution is adjusted with sodium hydroxide to the target pH for the dried protein and with ammonium hydroxide to obtain the selected pH for the protein solution to be spray-dried.

In one aspect of the invention, the volatile base is used to adjust the pH of the protein solution with at least about 0.5 pH unit, at least about 0.7 pH unit, or at least about 0.9 pH unit or at least about 1.1 pH unit, or at least about 1.3 pH unit or at least about 1.5 pH unit.

In solution, the self-association pattern of insulin is a complex function of protein concentration, metal ions, pH, ionic strength and solvent composition. For some of the currently used solutions containing insulin, zinc ions, salts and phenolic compounds, the following equilibria must be considered:



where In is insulin, In₂ is dimeric insulin, In₆ is hexameric insulin, T₆ is hexameric insulin in the T₆ conformation, T₃R₃ is hexameric insulin in the T₃R₃ conformation and R₆ is hexameric insulin in the hexameric R₆ state.

The known degradation patterns of insulin include a) fibril formation; b) deamidations at A18, A21 and B3; c) dimerisations via transamidation or Schiff-base formation; d) disulfide exchange reactions.

According to Brange (Stability of Insulin, Kluwer Academic Press, 1994), each of these degradation reactions proceed much faster in the monomeric state than in the hexameric state. Therefore, the most efficient means of stabilising insulin preparations is by pushing the above equilibrium as far to the right as possible. In addition to this general effect of mass action, the reactivity of selected residues is further modified depending on their direct involvement in the T → R conformational change. Thus, the reactivity of B3Asn is much lower in the R-state (when the residue resides in an alpha-helix) than in the T-state.

The interconversion between T₆, T₃R₃ and R₆ conformations of the two zinc insulin hexamer is modulated by ligand binding to the T₃R₃ and R₆ forms. Anions such as chloride have affinity for the fourth coordination position in the metal ions of T₃R₃ and R₆, while preservatives such as phenol binds to hydrophobic pockets located near the surfaces of the T₃R₃ and R₆ forms (Derewenda, Nature and, Brzovic, Biochemistry 33, 130557, 1994).

Therefore, conditions which favour the R₆ conformation of insulin in solution are an advantage both during the drying process in order to avoid denaturation of insulin and during shelf storage in order to maximise the chemical stability.

In one aspect of the invention the protein solution comprises phenol. In one aspect the protein solution comprises at least about 2 moles of phenol per mole of protein, or at least about 3 moles of phenol per mole of protein or at least about 4 moles of phenol per mole of protein. In one aspect the protein solution comprises about 4 moles of phenol per mole of insulin. In one aspect the protein solution comprises about 4 moles of phenol per

mole of insulin and the protein solution comprises zinc. When the protein solution comprises insulin, the phenol stabilises the insulin hexamer.

In one aspect of the invention the protein is selected from the group consisting of insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues and GLP-1 derivatives, glucagon and/or any combination thereof.

In one aspect of the invention the protein solution comprises a protein selected from the group consisting of insulin, insulin analogues, insulin derivatives and the solution further comprises zinc. The zinc content of the protein solution comprising insulin can be in the range of about 2 to about 4 zinc ions per insulin hexamer, or the zinc content can be in the range of about 2.1 to about 3 zinc ions per insulin hexamer or the zinc content can be in the range of about 2.2 to about 2.7 zinc ions per insulin hexamer. The zinc content of the protein solution comprising insulin can be about 2.3 zinc ions per insulin hexamer.

In one aspect of the invention the protein solution comprises a buffer, a detergent, a stabilizer, a protease inhibitor, a flavour, a carrier, an absorption protecting agent, a bulking agent or an agent improving the flowing properties or a penetration enhancer.

In one aspect of the invention the protein solution comprises glycylglycine. When glycylglycine is added to a protein solution, the protein dissolves more rapidly. In one aspect glycylglycine is added to an aqueous solution comprising insulin. The concentration of glycylglycine in the solution will be between about 4 mM and about 200 mM.

In one aspect of the invention the method for drying or spray-drying a protein solution a target pH for the dried protein is determined. The pH of the protein solution to be dried or spray-dried is above the target pH of the dried protein. The pH of the protein solution may be at least about 0.5 pH units above the pH of the dried protein. The pH of the protein solution may be at least about 0.7, at least about 0.9, at least about 1.1, at least about 1.3 or at least about 1.5, or at least about 2.0, or at least about 2.5 pH units above the pH of the of the spray-dried protein.

In one aspect of the invention the pH or the target pH of the spray dried protein is between about 6.0 and about 8.5, between about 6.2 and about 8.4, between about 6.4 and about 8.3, between about 6.6 and about 8.2, between about 6.8 and about 8.1, between about 7.0 and about 8.0, between about 7.2 and about 7.9, between about 7.4 and about 7.8 or between about 7.6 and about 7.7.

In one aspect of the invention the protein solution is dried or spray dried to obtain a water content below about 10%. The water content may be below about 6%, below about 4%, below about 2% or below about 1% calculated on/measured by loss on drying test (gravimetric) as stated in the experimental part.

In one aspect of the invention the protein to be dried or spray-dried is selected from the group consisting of AspB28 human insulin; LysB28ProB29 human insulin and LysB3GluB29 human insulin.

In one aspect the invention relates to a dried protein obtainable by the inventive process.

5 In one aspect the invention relates to a dried protein as described in the examples.

In one aspect the invention is related to a pharmaceutical composition comprising a therapeutically effective amount of a dried protein, such as insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues, GLP-1 derivatives, glucagon and/or any combination thereof according to the invention, which composition can be provided for the treatment of
10 type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia in patients in need of such a treatment.

In one aspect the invention is related to a pharmaceutical composition comprising a therapeutically effective amount of a dried protein, such as insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues, GLP-1 derivatives, glucagon and/or any combination thereof together with a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable additive, which composition can be provided for the treatment of type 1 diabetes,
15 type 2 diabetes and other states that cause hyperglycaemia in patients in need of such a treatment.

In one aspect of the invention, there is provided a method of treating type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia in a patient in need of such a treatment, comprising administering to the patient a therapeutically effective amount of an pharmaceutical composition comprising the dried protein according to the invention, such as insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues, GLP-1 derivatives, glucagon and/or any combination thereof.
20

In one aspect of the invention, there is provided a method of treating type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia in a patient in need of such a treatment, comprising administering to the patient a therapeutically effective amount of an pharmaceutical composition comprising the dried protein according to the invention, such as insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues, GLP-1 derivatives, glucagon and/or any combination thereof, optionally together with a pharmaceutically acceptable carrier and/or pharmaceutical acceptable additives.
25
30

In one aspect of the invention, there is provided a pharmaceutical composition for treating type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia in a patient in need of such a treatment, the composition comprising a therapeutically effective
35 amount of a dried protein according to the invention, such as insulin, insulin analogues, insu-

lin derivatives, GLP-1, GLP-1 analogues, GLP-1 derivatives, glucagon in mixture with one or two spray-dried proteins according to the invention, such as insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues, GLP-1 derivatives, glucagon optionally together with pharmaceutically acceptable carriers and/or additives.

5 In one aspect of the invention, there is provided a method of treating type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia in a patient in need of such a treatment, comprising administering to the patient a therapeutically effective amount of an pharmaceutical composition comprising a dried protein according to the invention, such as
10 insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues, GLP-1 derivatives, glucagon in mixture with one or two dried proteins according to the invention, such as insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues, GLP-1 derivatives, glucagon optionally together with a pharmaceutically acceptable carrier and/or pharmaceutical acceptable additives.

One aspect of the invention is related to a pharmaceutical composition comprising a
15 therapeutically effective amount of a dried protein according to the invention, such as insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues, GLP-1 derivatives, glucagon and/or any combination thereof, optionally together with a pharmaceutically acceptable carrier and/ or a pharmaceutically acceptable additive, which can be provided for pulmonary treatment of type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia in
20 patients in need of such a treatment.

In one aspect the invention is related to application of a pharmaceutical compositionn for pulmonary treatment of type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia in a patient in need of such a treatment, the pharmaceutical composition comprising a therapeutically effective amount of a dried protein according to the invention,
25 such as insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues, GLP-1 derivatives, glucagon and/or any combination thereof ,optionally in mixture with an insulin or an insulin analogue which has a rapid onset of action, together with pharmaceutically acceptable carriers and/or additives.

In one aspect of the invention, there is provided a method for the manufacture of a
30 pharmaceutical composition for the use in the treatment of type 1 diabetes, type 2 diabetes and other states that cause hyperglycaemia, the composition being used pulmonary and comprising a therapeutically effective amount of a dried protein according to the invention, such as insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues, GLP-1 derivatives, glucagon and/or any combination thereof, optionally in mixture with an insulin or an

insulin analogue which has a rapid onset of action, together with a pharmaceutically acceptable carrier and/or pharmaceutical acceptable additives.

PRODUCTION OF INSULIN

5 The insulin or a precursor thereof can be produced by either well-known peptide synthesis or by well known recombinant production in suitable transformed microorganisms. Thus the insulin can be produced by a method which comprises culturing a host cell containing a DNA sequence encoding the polypeptide and capable of expressing the polypeptide in a suitable nutrient medium under conditions permitting the expression of the peptide, after which the resulting peptide is recovered from the culture.

10 When preparing the insulin derivatives to be used in the pharmaceutical formulation according to the invention, the starting product for the substitution, the parent insulin or insulin analogue or a precursor thereof can be produced by either well-known peptide synthesis or by well known recombinant production in suitable transformed microorganisms. Thus the insulin starting product can be produced by a method which comprises culturing a host cell containing
15 a DNA sequence encoding the polypeptide and capable of expressing the polypeptide in a suitable nutrient medium under conditions permitting the expression of the peptide, after which the resulting peptide is recovered from the culture. Reference is made to international patent application WO 2005/012347.

PHARMACEUTICAL COMPOSITIONS

20 The dried protein of this invention can, for example, be administered subcutaneously, orally, nasally or pulmonary.

For subcutaneous administration, the dried insulin is formulated analogously with the formulation of known insulin. Furthermore, for subcutaneous administration, the dried insulin of this invention is administered analogously with the administration of known insulin
25 and, generally, the physicians are familiar with this procedure.

The dried insulin of this invention may be administered by inhalation in a dose effective manner to increase circulating insulin levels and/or to lower circulating glucose levels. Such administration can be effective for treating disorders such as diabetes or hyperglycaemia. Achieving effective doses of insulin requires administration of an inhaled dose of dried
30 insulin of this invention of more than about 0.5 µg/kg to about 50 µg/kg. A therapeutically effective amount can be determined by a knowledgeable practitioner, who will take into account factors including insulin level, blood glucose levels, the physical condition of the patient, the patient's pulmonary status, or the like.

According to the invention, dried insulin of this invention may be delivered by inhalation to achieve rapid absorption thereof. Administration by inhalation can result in pharmacokinetics comparable to subcutaneous administration of insulin. Inhalation of dried insulin of this invention leads to a rapid rise in the level of circulating insulin followed by a rapid fall in blood glucose levels. Different inhalation devices typically provide similar pharmacokinetics when similar particle sizes and similar levels of lung deposition are compared.

According to the invention, dried insulin of this invention may be delivered by any of a variety of inhalation devices known in the art for administration of a therapeutic agent by inhalation. These devices include metered dose inhalers, nebulizers, dry powder generators, sprayers, and the like. dried insulin of this invention is delivered by a dry powder inhaler or a sprayer. There are a several desirable features of an inhalation device for administering dried insulin of this invention. For example, delivery by the inhalation device is advantageously reliable, reproducible, and accurate. The inhalation device should deliver small particles, for example particles less than about 10 μm , for example about 1-5 μm , for good respirability.

Some specific examples of commercially available inhalation devices suitable for the practice of this invention are TurbohalerTM (Astra), Rotahaler[®] (Glaxo), Diskus[®] (Glaxo), SpirosTM inhaler (Dura), devices marketed by Inhale Therapeutics, AERxTM (Aradigm), the Ultravent[®] nebulizer (Mallinckrodt), the Acorn II[®] nebulizer (Marquest Medical Products), the Ventolin[®] metered dose inhaler (Glaxo), the Spinhaler[®] powder inhaler (Fisons), or the like.

As those skilled in the art will recognize, the formulation of dried protein of the invention, the quantity of the formulation delivered, and the duration of administration of a single dose depend on the type of inhalation device employed. For some aerosol delivery systems, such as nebulizers, the frequency of administration and length of time for which the system is activated will depend mainly on the concentration of insulin conjugate in the aerosol. For example, shorter periods of administration can be used at higher concentrations of insulin conjugate in the nebulizer solution. Devices such as metered dose inhalers can produce higher aerosol concentrations, and can be operated for shorter periods to deliver the desired amount of insulin conjugate. Devices such as powder inhalers deliver active agent until a given charge of agent is expelled from the device. In this type of inhaler, the amount of dried insulin of this invention in a given quantity of the powder determines the dose delivered in a single administration.

The particle size of dried insulin of this invention in the formulation delivered by the inhalation device is critical with respect to the ability of insulin to make it into the lungs, and into the lower airways or alveoli. The dried insulin of this invention can be formulated so that at least about 10% of the insulin conjugate delivered is deposited in the lung, for example

about 10 to about 20%, or more. It is known that the maximum efficiency of pulmonary deposition for mouth breathing humans is obtained with particle sizes of about 2 μm to about 3 μm . Pulmonary deposition decreases substantially when particle sizes are above about 5 μm . Particle sizes below about 1 μm cause pulmonary deposition to decrease, and it becomes difficult to deliver particles with sufficient mass to be therapeutically effective. Thus, particles of dried protein delivered by inhalation have a particle size less than about 10 μm , for example in the range of about 1 μm to about 5 μm . The formulation of dried protein is selected to yield the desired particle size in the chosen inhalation device.

Advantageously for administration as a dry powder, dried protein of this invention is prepared in a particulate form with a particle size of less than about 10 μm , for example about 1 to about 5 μm . The particle size is effective for delivery to the alveoli of the patient's lung. The dry powder is largely composed of particles produced so that a majority of the particles have a size in the desired range. Advantageously, at least about 50% of the dry powder is made of particles having a diameter less than about 10 μm .

The particles are usually separated from a dry powder formulation in a container and then transported into the lung of a patient via a carrier air stream. Typically, in current dry powder inhalers, the force for breaking up the solid is provided solely by the patient's inhalation. In another type of inhaler, air flow generated by the patient's inhalation activates an impeller motor which deagglomerates the particles.

Formulations of dried protein of this invention for administration from a dry powder inhaler typically include a finely divided dry powder containing the dried protein, but the powder can also include a bulking agent, carrier, excipient, another additive, or the like. Additives can be included in a dry powder formulation of insulin conjugate, for example, to dilute the powder as required for delivery from the particular powder inhaler, to facilitate processing of the formulation, to provide advantageous powder properties to the formulation, to facilitate dispersion of the powder from the inhalation device, to stabilize the formulation (for example, antioxidants or buffers), to provide taste to the formulation, or the like. Advantageously, the additive does not adversely affect the patient's airways. The dried protein can be mixed with an additive at a molecular level or the solid formulation can include particles of the protein conjugate mixed with or coated on particles of the additive. Typical additives include mono-, di-, and polysaccharides; sugar alcohols and other polyols, such as, for example, lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol, starch, or combinations thereof; surfactants, such as sorbitols, diphosphatidyl choline, or lecithin; or the like. Typically an additive, such as a bulking agent, is present in an amount effective for a purpose described above, often at about 50% to about 99% by weight of the formulation. Ad-

ditional agents known in the art for formulation of a protein such as insulin analogue protein can also be included in the formulation.

The protein solution may optionally be combined with pharmaceutical carriers or excipients which are suitable for respiratory and pulmonary administration. Such carriers may serve
5 simply as bulking agents when it is desired to reduce the insulin concentration in the powder which is being delivered to a patient, but may also serve to enhance the stability of the insulin compositions and to improve the dispersability of the powder within a powder dispersion device in order to provide more efficient and reproducible delivery of the insulin and to improve
10 handling characteristics of the insulin such as flowability and consistency to facilitate manufacturing and powder filling.

Suitable carrier materials may be in the form of an amorphous powder, a crystalline powder, or a combination of amorphous and crystalline powders. Suitable materials include carbohydrates, e.g., monosaccharides such as fructose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, trehalose, cellobiose, and the like; cyclodextrins,
15 such as 2-hydroxypropyl--cyclodextrin; and polysaccharides, such as raffinose, maltodextrins, dextrans, and the like; (b) amino acids, such as glycine, arginine, aspartic acid, glutamic acid, cysteine, lysine, and the like; (c) organic salts prepared from organic acids and bases, such as sodium citrate, sodium ascorbate, magnesium gluconate, sodium gluconate, tromethamine hydrochloride, and the like; (d) peptides and proteins, such as aspartame, hu-
20 man serum albumin, gelatin, and the like; (e) alditols, such as mannitol, xylitol, and the like. A preferred group of carriers includes lactose, trehalose, raffinose, maltodextrins, glycine, sodium citrate, tromethamine hydrochloride, human serum albumin, and mannitol.

Such carrier materials may be combined with the insulin prior to spray drying, i.e., by adding the carrier material to the protein solution or the aqueous which is prepared for spray drying.

25 In that way, the carrier material will be formed simultaneously with and as part of the protein particles.

Typically, when the carrier is formed by spray drying together with the protein, the protein will be present in each individual particle at a weight percent in the range from 5% to 95%, preferably from 20% to 80%. The remainder of the particle will primarily be carrier material (typi-
30 cally being from 5% to 95%, usually being from 20% to 80% by weight), but will also include buffer (s) may include other components as described above.

Alternatively, the carriers may be separately prepared in a dry powder form and combined with the dry powder protein by blending. The separately prepared powder carriers will usually be crystalline (to avoid water absorption), but might in some cases be amorphous or mixtures
35 of crystalline and amorphous. The size of the carrier particles may be selected to improve the

flowability of the insulin powder, typically being in the range from 25m to 100m. Carrier particles in this size range will generally not penetrate into the alveolar region of the lung and will often separate from the insulin in the delivery device prior to inhalation. Thus, the particles which penetrate into the alveolar region of the lung will consist essentially of insulin and
5 buffer. A preferred carrier material is crystalline mannitol having a size in the above-stated range.

The dry insulin powders of the present inventions may also be combined with other active components. For example, it may be desirable to combine small amounts of amylin or active amylin analogues in the insulin powders to improve the treatment of diabetes. Amylin is a
10 hormone which is secreted with insulin from the pancreatic β -cells in normal (non-diabetic) individuals. It is believed that amylin modulates insulin activity in vivo, and it has been proposed that simultaneous administration of amylin with insulin could improve blood glucose control. Combining dry powder amylin with insulin in the compositions of the present invention will provide a particularly convenient product for achieving such simultaneous admini-
15 stration. Amylin may be combined with insulin at from 0.1% by weight to 10% by weight (based on the total weight of insulin in a dose), preferably from 0.5% by weight to 2.5% by weight. Amylin is available from commercial suppliers, such as Amylin Corporation, San Diego, California, and can be readily formulated in the compositions of the present invention. For example, amylin may be dissolved in aqueous or other suitable solutions together with
20 the insulin, and optionally carriers, and the solution spray dried to produce the powder product.

A spray including the dried protein of this invention can be produced by forcing a suspension or solution of protein conjugate through a nozzle under pressure. The nozzle size and configuration, the applied pressure, and the liquid feed rate can be chosen to achieve
25 the desired output and particle size. An electrospray can be produced, for example, by an electric field in connection with a capillary or nozzle feed. Advantageously, particles of insulin conjugate delivered by a sprayer have a particle size less than about 10 μm , for example in the range of about 1 μm to about 5 μm .

Formulations of dried protein of this invention suitable for use with a sprayer will
30 typically include proteins in an aqueous solution at a concentration of about 1 mg to about 20 mg of protein conjugate per ml of solution. The formulation can include agents such as an excipient, a buffer, an isotonicity agent, a preservative, a surfactant, and, for example zinc. The formulation can also include an excipient or agent for stabilization of the crystals, such as a buffer, a reducing agent, a bulk protein, or a carbohydrate. Bulk proteins useful in formu-
35 lating dried protein conjugates include albumin, protamine, or the like. Typical carbohydrates

useful in formulating protein conjugates include sucrose, mannitol, lactose, trehalose, glucose, or the like. The crystal formulation can also include a surfactant, which can reduce or prevent surface-induced aggregation of the insulin conjugate caused by atomization of the solution in forming an aerosol. Various conventional surfactants can be employed, such as polyoxyethylene fatty acid esters and alcohols, and polyoxyethylene sorbitol fatty acid esters. Amounts will generally range between about 0.001 and about 4% by weight of the formulation.

Pharmaceutical compositions containing a dried protein according to the present invention may also be administered nasally. The pharmaceutical composition may be administered as a liquid composition, a dry composition or a gel. For drug delivery via the nose the crystals may be above 10 μm in order to secure deposition in the nasal cavity and to avoid that the particles are carried further down to the tracheobronchial and pulmonary region. There is no clear understanding of a upper size limit, but there probably is an upper particle size above which particles for a number of reasons will not demonstrate efficacy and maybe even could lead to local irritation.

Pharmaceutical compositions containing a dried protein according to the present invention may also be administered parenterally to patients in need of such a treatment. Parenteral administration may be performed by subcutaneous, intramuscular or intravenous injection by means of a syringe, optionally a pen-like syringe. Alternatively, parenteral administration can be performed by means of an infusion pump.

Injectable compositions of the dried protein of the invention can be prepared using the conventional techniques of the pharmaceutical industry which involve dissolving and mixing the ingredients as appropriate to give the desired end product. Thus, according to one procedure, a crystal comprising insulin according to the invention is dissolved in an amount of water which is somewhat less than the final volume of the composition to be prepared. An isotonic agent, a preservative and a buffer is added as required and the pH value of the solution is adjusted - if necessary - using an acid, e.g. hydrochloric acid, or a base, e.g. aqueous sodium hydroxide as needed. Finally, the volume of the solution is adjusted with water to give the desired concentration of the ingredients.

In a further aspect of the invention the buffer is selected from the group consisting of sodium acetate, sodium carbonate, citrate, glycylglycine, histidine, glycine, lysine, arginine, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium phosphate, and tris(hydroxymethyl)-aminomethan, bicine, tricine, malic acid, succinate, maleic acid, fumaric

acid, tartaric acid, aspartic acid or mixtures thereof. Each one of these specific buffers constitutes an alternative aspect of the invention.

In a further aspect of the invention the formulation further comprises a pharmaceutically acceptable preservative which may be selected from the group consisting of phenol, o-cresol, m-cresol, p-cresol, methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, 2-phenoxyethanol, butyl p-hydroxybenzoate, 2-phenylethanol, benzyl alcohol, chlorobutanol, and thiomerosal, bronopol, benzoic acid, imidurea, chlorohexidine, sodium dehydroacetate, chlorocresol, ethyl p-hydroxybenzoate, benzethonium chloride, chlorphenesine (3p-chlorphenoxypropane-1,2-diol) or mixtures thereof. In a further aspect of the invention the preservative is present in a concentration from 0.1 mg/ml to 20 mg/ml. In a further aspect of the invention the preservative is present in a concentration from 0.1 mg/ml to 5 mg/ml. In a further aspect of the invention the preservative is present in a concentration from 5 mg/ml to 10 mg/ml. In a further aspect of the invention the preservative is present in a concentration from 10 mg/ml to 20 mg/ml. Each one of these specific preservatives constitutes an alternative aspect of the invention. The use of a preservative in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: *The Science and Practice of Pharmacy*, 19th edition, 1995.

In a further aspect of the invention the formulation further comprises an isotonic agent which may be selected from the group consisting of a salt (e.g. sodium chloride), a sugar or sugar alcohol, an amino acid (e.g. glycine, L-histidine, arginine, lysine, isoleucine, aspartic acid, tryptophan, threonine), an alditol (e.g. glycerol (glycerine), 1,2-propanediol (propyleneglycol), 1,3-propanediol, 1,3-butanediol) polyethyleneglycol (e.g. PEG400), or mixtures thereof. Any sugar such as mono-, di-, or polysaccharides, or water-soluble glucans, including for example fructose, glucose, mannose, sorbose, xylose, maltose, lactose, sucrose, trehalose, dextran, pullulan, dextrin, cyclodextrin, soluble starch, hydroxyethyl starch and carboxymethylcellulose-Na may be used. In one aspect the sugar additive is sucrose. Sugar alcohol is defined as a C4-C8 hydrocarbon having at least one --OH group and includes, for example, mannitol, sorbitol, inositol, galactitol, dulcitol, xylitol, and arabitol. In one aspect the sugar alcohol additive is mannitol. The sugars or sugar alcohols mentioned above may be used individually or in combination. There is no fixed limit to the amount used, as long as the sugar or sugar alcohol is soluble in the liquid preparation and does not adversely effect the stabilizing effects achieved using the methods of the invention. In one aspect, the sugar or sugar alcohol concentration is between about 1 mg/ml and about 150 mg/ml. In a further aspect of the invention the isotonic agent is present in a concentration from 1 mg/ml to 50 mg/ml. In a further aspect of the invention the isotonic

agent is present in a concentration from 1 mg/ml to 7 mg/ml. In a further aspect of the invention the isotonic agent is present in a concentration from 8 mg/ml to 24 mg/ml. In a further aspect of the invention the isotonic agent is present in a concentration from 25 mg/ml to 50 mg/ml. Each one of these specific isotonic agents constitutes an alternative aspect of the invention. The use of an isotonic agent in pharmaceutical compositions is well-known to the skilled person. For convenience reference is made to Remington: *The Science and Practice of Pharmacy*, 19th edition, 1995.

Typical isotonic agents are sodium chloride, mannitol, dimethyl sulfone and glycerol and typical preservatives are phenol, m-cresol, methyl p-hydroxybenzoate and benzyl alcohol.

Examples of suitable buffers are sodium acetate, glycylglycine, HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) and sodium phosphate.

Compositions containing dried protein of this invention, such as insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues, GLP-1 derivatives, glucagon can be used in the treatment of states which are sensitive to insulin. Thus, they can be used in the treatment of type 1 diabetes, type 2 diabetes and hyperglycaemia for example as sometimes seen in seriously injured persons and persons who have undergone major surgery. The optimal dose level for any patient will depend on a variety of factors including the efficacy of the specific insulin employed, the age, body weight, physical activity, and diet of the patient, on a possible combination with other drugs, and on the severity of the state to be treated. It is recommended that the daily dosage of the dried protein of this invention be determined for each individual patient by those skilled in the art in a similar way as for known pharmaceutical compositions.

Where expedient, the dried protein of this invention may be used in mixture with other types of proteins, e.g. insulin analogues with a more rapid onset of action. Examples of such insulin analogues are described e.g. in the European patent applications having the publication Nos. EP 214826 (Novo Nordisk A/S), EP 375437 (Novo Nordisk A/S) and EP 383472 (Eli Lilly & Co.).

All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference in their entirety and to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law).

All headings and sub-headings are used herein for convenience only and should not be construed as limiting the invention in any way.

The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should

be construed as indicating any non-claimed element as essential to the practice of the invention.

The citation and incorporation of patent documents herein is done for convenience only and does not reflect any view of the validity, patentability, and/or enforceability of such
5 patent documents.

This invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law.

The invention will be summarised in the following paragraphs:

1. A process for drying a protein solution, wherein
 - a) a protein solution is obtained by mixing a protein with water optionally comprising excipients and adjusting the pH with a volatile base, a non volatile base and optionally a non volatile acid for the protein solution to become alkaline, and
 - b) drying the protein solution
2. A process according to paragraph 1 comprising:
 - a) Selecting a target pH for the dried protein,
 - b) Selecting a target pH for the protein solution,
 - c) Providing an aqueous phase,
 - d) Adding a protein,
 - e) Optionally adding excipients,
 - f) Adjusting the pH with a non volatile base and optionally a non volatile acid to the target pH for the dried protein,
 - g) Adjusting the pH with a volatile base to the target pH of the protein solution to be dried, and
 - h) Spray-drying the protein solution.wherein the steps d, e, f and g can be carried out in any order while stirring continuously.
3. A process according to paragraph 2, wherein the steps d, e and f can be carried out in any order while stirring continuously.
4. The process according to paragraphs 1-3, wherein the protein solution is obtained at a temperature below 8°C.
5. The process according to paragraphs 1-4, wherein the protein solution is obtained at a temperature below 6°C, below 5°C, below 4°C, below 3°C, below 2°C or below 1°C.
6. The process according to paragraphs 1-5, wherein the freezing point of the aqueous phase is depressed and a protein solution is obtained at a temperature below 0°C.
7. The process according to paragraphs 1-6, wherein the drying method is selected from the group consisting of spray drying, spray freeze drying, fluid bed drying, freeze drying and vacuum drying.
8. The process according to paragraphs 1-7, wherein the protein solution has a pH above 7.4.
9. The process according to paragraphs 1-8, wherein the protein solution has a pH above 7.6, above 7.8, above 8.0, above 8.2, above 8.4 or above 8.6.
10. The process according to paragraphs 1-8, wherein the protein solution has a pH between 7.4 and 11.0.

11. The process according to paragraphs 1-8 and 10, wherein the protein solution has a pH between about 7.6 and about 11.0, between about 7.6 and about 10.5, between about 7.8 and about 11.0, between about 7.8 and about 10.5, between about 8.0 and about 11.0, between about 8.0 and about 10.5, between about 8.2 and about 11.0, between about 8.4 and about 11.0, between about 8.6 and about 10.0, between about 8.8 and about 10.0, between about 9.0 and about 10.0 or between about 9.2 and about 10.0.
12. The process according to paragraphs 1-11, wherein the non volatile base is selected from the group consisting of alkaline metal salts, alkaline metal hydroxides, alkaline earth metal salts, alkaline earth metal hydroxides and amino acids or a combination hereof.
13. The process according to paragraph 12, wherein the non volatile base is sodium hydroxide, potassium hydroxide, calcium hydroxide, calcium oxide or any combination hereof.
14. The process according to paragraphs 1-13, wherein the volatile base is selected from the group consisting of ammonium hydroxides, tetraalkylammonium hydroxides, secondary amines, tertiary amines, aryl amines, aliphatic amines or ammonium bicarbonate or a combination hereof.
15. The process according to paragraph 14, wherein the volatile base is ammonium hydroxide, ethyl amine or methyl amine or a combination hereof.
16. The process according to paragraphs 1-15, wherein the volatile base adjusts the pH of the protein solution with at least 0.5 pH unit.
17. The process according to paragraphs 1-16, wherein the volatile base adjusts the pH of the protein solution with at least 0.7 pH unit, or at least 0.9 pH unit or at least 1.1 pH unit, or at least 1.3 pH unit or at least 1.5 pH unit.
18. The process according to paragraphs 1-17, wherein the pH of the protein solution is adjusted with a solution comprising sodium hydroxide and ammonium hydroxide.
19. The process according to paragraphs 1-18, wherein the protein is selected from the group consisting of insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues and GLP-1 derivatives, glucagon and/or any combination thereof.
20. The process according to paragraphs 1-19, wherein the protein solution comprises a protein selected from the group consisting of insulin, insulin analogues, insulin derivatives and the solution further comprises zinc.
21. The process according to paragraph 20, wherein the protein solution comprises phenol.
22. The process according to paragraphs 20-21, where in the protein solution comprises about 4 moles of phenol per mole of protein.
23. The process according to paragraphs 1-22, wherein the protein solution comprises a buffer, a detergent, a stabilizer, a protease inhibitor, a flavour, a carrier, an absorption pro-

tacting agent, a bulking agent or an agent improving the flowing properties or a penetration enhancer or a combination hereof

24. The process according to paragraph 23, wherein the protein solution comprises glycyl-glycine

5 25. The process according to paragraphs 1-24, wherein the pH of the protein solution is above the pH of the dried protein.

26. The process according to paragraph 25, wherein the pH of the protein solution is at least 0.5 pH units above the pH of the dried protein.

10 27. The process according to paragraphs 1-26, wherein the pH of the protein solution is at least 0.7, at least 0.9, at least 1.1, at least 1.3 or at least 1.5 pH units above the pH of the of the dried protein.

28. The process according to paragraphs 1-27, wherein the pH of the dried protein is between about 6.0 and about 8.5.

15 29. The process according to paragraphs 1-28, wherein the pH of the dried protein is between about 6.2 and about 8.4, between about 6.4 and about 8.3, between about 6.6 and about 8.2, between about 6.8 and about 8.1, between about 7.0 and about 8.0, between about 7.2 and about 7.9, between about 7.4 and about 7.8 or between about 7.6 and about 7.7.

20 30. The process according to paragraphs 1-29, wherein the protein solution is dried to obtain a water content of the spray dried protein below about 10%, below about 6%, below about 4%, below about 2% or below about 1%.

31. The process according to paragraphs 1-30, wherein the protein is an insulin analogue is selected from the group consisting of AspB28 human insulin; LysB28ProB29 human insulin and LysB3GluB29 human insulin.

25 32. Dried protein obtainable by the process of paragraphs 1-31.

33. Pharmaceutical composition comprising a therapeutically effective amount of a spray-dried protein according to paragraph 32.

34. Pharmaceutical composition according to paragraph 33 wherein the composition is for pulmonary, parenteral, nasal or oral treatment of diabetes or hyperglycaemia.

30 35. Pharmaceutical composition for the treatment of diabetes or hyperglycaemia in a patient in need of such treatment, comprising a therapeutically effective amount of a dried protein according to paragraph 32, wherein the protein is selected from the group consisting of insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues, GLP-1 derivatives, glucagon and/or any combination thereof .

36. A method of treating diabetes in a patient in need of such a treatment, comprising administering to the patient a therapeutically effective amount of a dried protein according to any of the paragraph 32 or a pharmaceutical composition according to paragraphs 33-35.

37. A method according to paragraph 36, wherein the protein is selected from the group consisting of insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues, GLP-1 derivatives, glucagon and/or any combination thereof

38. Dried protein as described in the examples.

1a. A process for drying an protein solution, wherein

- 10 a) A protein solution is obtained by mixing a protein with water optionally comprising excipients and adjusting the pH to become alkaline, and
b) Drying the protein solution.

2a. A process for producing a dried protein from a protein solution comprising:

- 15 a) Selecting a target pH for the dried protein,
b) Selecting a target pH for the protein solution,
c) Providing an aqueous phase,
d) Adding a protein,
e) Optionally adding excipients,
f) Adjusting the pH with a non volatile base to the target pH for the dried protein,
20 g) Adjusting the pH with a volatile base to the target pH of the protein solution to be dried, and
h) Spray-drying the protein solution.

wherein the steps d, e, f and g can be carried out in any order while stirring continuously.

3a. The process according to paragraph 1a, wherein the protein solution is adjusted with a volatile base and a non volatile base.

4a. The process according to paragraphs 1a-3a, wherein the protein solution is obtained at a temperature below 8°C.

5a. The process according to paragraphs 1a-4a, wherein the protein solution is obtained at a temperature below 6°C, below 5°C, below 4°C, below 3°C, below 2°C or below 1°C.

30 6a. The process according to paragraphs 1a-5a, wherein the freezing point of the aqueous phase is depressed and a protein solution is obtained at a temperature below 0°C.

7a. The process according to paragraphs 1a-6a, wherein the drying method is selected from the group consisting of spray drying, spray freeze drying, fluid bed drying, freeze drying and vacuum drying.

8a. The process according to paragraphs 1a-7a, wherein the protein solution has a pH above 7.4.

9a. The process according to paragraphs 1a-8a, wherein the protein solution has a pH above 7.6, above 7.8, above 8.0, above 8.2, above 8.4 or above 8.6.

5 10a. The process according to paragraphs 1a-8a, wherein the protein solution has a pH between 7.4 and 11.0.

11a. The process according to paragraphs 1a-8a and 10a, wherein the protein solution has a pH between about 7.6 and about 11.0, between about 7.6 and about 10.5, between about 7.8 and about 11.0, between about 7.8 and about 10.5, between about 8.0 and about 11.0,
10 between about 8.0 and about 10.5, between about 8.2 and about 11.0, between about 8.4 and about 11.0, between about 8.6 and about 10.0, between about 8.8 and about 10.0, between about 9.0 and about 10.0 or between about 9.2 and about 10.0.

12a. The process according to paragraphs 1a-11a, wherein the non volatile base is selected from the group consisting of alkaline metal salts, alkaline metal hydroxides, alkaline earth
15 metal salts, alkaline earth metal hydroxides and amino acids or a combination hereof.

13a. The process according to paragraph 12a, wherein the non volatile base is sodium hydroxide, potassium hydroxide, calcium hydroxide, calcium oxide or any combination hereof.

14a. The process according to paragraphs 1a-11a, wherein the volatile base is selected from the group consisting of ammonium hydroxides, tetraalkylammonium hydroxides, secondary
20 amines, tertiary amines, aryl amines, aliphatic amines or ammonium bicarbonate or a combination hereof.

15a. The process according to paragraph 14a, wherein the volatile base is ammonium hydroxide, ethyl amine or methyl amine or a combination hereof.

16a. The process according to paragraphs 1a-15a, wherein the volatile base adjusts the pH
25 of the protein solution with at least 0.5 pH unit.

17a. The process according to paragraphs 1a-16a, wherein the volatile base adjusts the pH of the protein solution with at least 0.7 pH unit, or at least 0.9 pH unit or at least 1.1 pH unit, or at least 1.3 pH unit or at least 1.5 pH unit.

18a. The process according to paragraphs 1a-17a, wherein the pH of the protein solution is
30 adjusted with a solution comprising sodium hydroxide and ammonium hydroxide.

19a. The process according to paragraphs 1a-18a, wherein the protein solution comprises phenol.

20a. The process according to paragraphs 1a-19a, wherein the protein is selected from the group consisting of insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues,

GLP-1 derivatives, exendin, exendin analogues and derivatives and/or any combination thereof.

21a. The process according to paragraphs 1a-20a, wherein the protein is selected from the group consisting of amylin, amylin analogues, amylin derivatives, α -MSH, α -MSH analogues, α -MSH derivatives and/or any combination thereof.

22a. The process according to paragraphs 1a-20a, wherein the protein solution comprises a protein selected from the group consisting of insulin, insulin analogues, insulin derivatives and the solution further comprises zinc.

23a. The process according to paragraphs 1a-22a, wherein the protein solution comprises a buffer, a detergent, a stabilizer, a protease inhibitor, a flavour, a carrier, an absorption promoting agent, a bulking agent or an agent improving the flowing properties or a penetration enhancer or a combination hereof

24a. The process according to paragraph 23a, wherein the protein solution comprises glycylglycine

25a. The process according to paragraphs 1a-24a, wherein the pH of the protein solution is above the pH of the dried protein.

26a. The process according to paragraph 25a, wherein the pH of the protein solution is at least 0.5 pH units above the pH of the dried protein.

27a. The process according to paragraphs 1a-26a, wherein the pH of the protein solution is at least 0.7, at least 0.9, at least 1.1, at least 1.3 or at least 1.5 pH units above the pH of the dried protein.

28a. The process according to paragraphs 1a-27a, wherein the pH of the dried protein is between about 6.0 and about 8.5.

29a. The process according to paragraphs 1a-28a, wherein the pH of the dried protein is between about 6.2 and about 8.4, between about 6.4 and about 8.3, between about 6.6 and about 8.2, between about 6.8 and about 8.1, between about 7.0 and about 8.0, between about 7.2 and about 7.9, between about 7.4 and about 7.8 or between about 7.6 and about 7.7.

30a. The process according to paragraphs 1a-29a, wherein the protein solution is dried to obtain a water content of the spray dried protein below about 10%, below about 6%, below about 4%, below about 2% or below about 1%.

31a. The process according to paragraphs 1a-30a, wherein the protein is an insulin analogue is selected from the group consisting of AspB28 human insulin; LysB28ProB29 human insulin and LysB3GluB29 human insulin.

32a. Dried protein obtainable by the process of paragraphs 1a-31a.

33a. Pharmaceutical composition comprising a therapeutically effective amount of a spray-dried protein according to paragraph 32a.

34a. Pharmaceutical composition according to paragraph 33a wherein the composition is for pulmonary, parenteral, nasal or oral treatment of diabetes or hyperglycaemia.

5 35a. Pharmaceutical composition for the treatment of diabetes or hyperglycaemia in a patient in need of such treatment, comprising a therapeutically effective amount of a dried protein according to paragraph 32a, wherein the protein is selected from the group consisting of insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues, GLP-1 derivatives, exendin, exendin analogues and derivatives and/or any combination thereof .

10 36a. A method of treating diabetes in a patient in need of such a treatment, comprising administering to the patient a therapeutically effective amount of a dried protein according to any of the paragraph 32a or a pharmaceutical composition according to paragraphs 33a-35a.

37a. A method according to paragraph 36a, wherein the protein is selected from the group consisting of insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues, GLP-1

15 derivatives, exendin, exendin analogues and derivatives and/or any combination thereof

38a. Dried protein as described in the examples.

ANALYTICAL METHODS

20 HMWP content was determined by a isocratic size exclusion chromatography method based on a Ph. Eur method. A Waters Insulin HMWP 7,8 x 300 mm column was used with a mobile phase consisting of 65 % 1.0 mg/ml L-arginine solution, 20 % acetonitrile, and 15 % glacial acetic acid at a flow of 0.5 ml/min. Injection volumes were 100 µl. The column temperature was ambient. Detection was made by ultraviolet absorbance at 276 nm. Chromatograms were analyzed on a peak area versus total peak area basis.

25

Purity was determined with a reversed-phase chromatography method utilizing a Waters Sunfire C18, 3.5 µm, 150 x 4.6 mm i.d. column. The column temperature was 35°C and the flow rate was 1 ml/min. A gradient system was used with mobile phase A containing 1.4 % (w/w) sodium sulfate, 0.2 % (w/w) o-phosphoric acid, 7.7 % (w/w) acetonitrile, pH 3.6 and mobile phase B containing 42.8 % (w/w) acetonitrile in water. The gradient system began isocratically at approximately 42 % mobile phase B for 30 min. Mobile phase B was then increase linearly from 42 % to 80 % over 3 min and remained isocratically for 2 minutes. Initial conditions then returned to 42 % mobile phase B over 1 min and was remained for 20 min. Detection was by ultraviolet absorbance at 214 nm. Injection volume was 10 µl. Chro-

matograms were analysed on a peak area versus total peak area basis. The method detects insulin related impurities including desamido forms of insulin and is reported as insulin related impurities.

5 The volume particle size distribution of the spray-dried powders was determined using a laser diffraction apparatus, Mastersizer (Malvern Instruments, United Kingdom) operated in wet mode. The apparatus was equipped with a wet dispersion system (Malvern QS Small Volume Sample Dispersion Unit) in which the microparticles was suspended in isopropanol containing approximately 0.05 % Tween 80. Then sample is measure and based on
10 the scattering data a particle size distribution is calculated using Malvern software. The volume median diameter $D[v,0.5]$ is the diameter where 50% of the distribution is above and 50% is below.

 The aerodynamic particle size distribution of the spray dried powders was determined using a model 3321 Aerodynamic Particle Sizer® (APS) spectrometer (TSI incorporated), which is a laser based particle sizing instrument that measures the aerodynamic diameter of individual particles based on the particles velocities immediately downstream of a flow accelerating nozzle. The powders were aerosolized with a Small Scale powder Disperser model 3433 (TSI incorporated). From these measurements, size distributions are determined in nearly real time. The mass median aerodynamic diameter (MMAD) is the aerodynamic diameter where 50% of the distribution is above and 50% is below.
15
20

 Residual moisture content of the spray dried powder was determined by loss on drying at 110°C for minimum 3 hours using a PerkinElmer Pyris TGA1 thermogravimetric analyzer. The weight change caused by moisture loss was registered and expressed in percent by weight.
25

EXAMPLES

EXAMPLE 1

30 Dissolution of insulin human at pH 9.5

 10.0 g of insulin human was dispersed in 387.3 g ice cold water. The dispersion was placed on ice bath and the pH was measured to pH 5.03. Ice cold 0.2 N sodium hydroxide was then added step wise until pH 8.99. After 45 minutes pH was decreased to 8.77 and

over the next 4 hours ice cold 0.2 N sodium hydroxide was added until pH 8.75. The solution was still not clear and it was placed in a refrigerator over night.

The next day pH was measured to 8.75 and the solution was still not clear. pH was adjusted to 9.48 with ice cold 0.2 N sodium hydroxide and the unclear solution was then placed in the refrigerator for the next 5 days.

After 5 days the solution was clear and pH was adjusted from 9.37 until 7.59 with 0.2 N hydrogen chloride.

EXAMPLE 2

- 10 A) Spray drying of protein solution with volatile base and
- B) Measurement of pH of spray dried protein

9.5 g of insulin human was dispersed in 200 g ice cold water. The suspension was placed on ice bath and the initial pH was measured to pH 5.12. The pH was adjusted to 7.04 with 5.8 g of ice cold 0.2 N sodium hydroxide. The solution remained on ice bath for another 2 hour and then demineralised water was added to a total weight of 240 g.

50 g of the pH 7.04 solution was further processed. The pH was adjusted from 7.04 to 7.50 with ice cold 1 N NH_4OH and was then placed in a refrigerator overnight. The next day pH was measured to 7.32 and pH was adjusted with ice cold 1 N NH_4OH to pH 8.06. Then water was added up to 60.0 g. The final concentration of insulin human was approximately 30 mg/ml.

Dry, solid microparticles were prepared on a Büchi B-290 mini spray dryer (Büchi, Labortechnik AG Flawil, Switzerland) equipped with a 0.7 mm co-current two-fluid nozzle. The insulin human solution was atomised into hot air stream in a drying chamber at a liquid feed rate of 2 ml/min and atomising air flow of 600-800 liter/hour.

The drying air had an inlet temperature of 150°C and a drying air flow rate of 35 m³/hour. The outlet temperature was approximately 70°C.

Solid microparticles were captured by a cyclone connected to the drying chamber and then gathered and stored at dry conditions.

30 Spray dried insulin human (protein solution pH was 8.06 before spray drying) were re-dissolved in demineralised water at concentrations at 40 mg/mL, 80 mg/mL and 160 mg/mL to investigate if the different concentrations have influence of the measured pH value:

25.3 mg was added 633 μL water: pH was measured to 6.95

35 43.5 mg was added 545 μL water: pH was measured to 6.95

81.7 mg was added 510 µL water: pH was measured to 7.01

EXAMPLE 3

Spray drying of insulin aspart (B28^{Asp} human insulin) dissolved by various ratio of
5 volatile and non-volatile base.

Various insulin aspart solutions with and without stabilising excipients were prepared prior to spray drying:

Preparation A

10 Solution A1: 16 g insulin aspart was suspended in 150 ml water on an ice bath. Next, 2.6 ml of ice cold concentrated aqueous ammonia (25 % w/w) was added stepwise until pH was 7.53 and a clear solution was obtained. Finally, water was added to a total volume of 200 ml. The concentration of insulin aspart was 80 mg/ml.

Solution A2: 65 ml of solution A1 was diluted further to 130 ml. The concentration of
15 insulin aspart was 40 mg/ml.

Preparation B

Solution B1: 16 g insulin aspart was suspended in 150 ml water on an ice bath. Initially, 2.2 ml of ice cold 1 N NaOH and then 750 µl ice cold concentrated aqueous ammonia
20 (25 % w/w) was added stepwise until pH was 7.52 and a clear solution was obtained. Finally, water was added to a total volume of 200 ml. The concentration of insulin aspart was 80 mg/ml.

Solution B2: 65 ml of solution B1 was diluted further to 130 ml. The concentration of
insulin aspart was 40 mg/ml.

25

Preparation C

Solution C1: 16 g insulin aspart was suspended in 150 ml water on an ice bath. Initially, 4.4 ml of ice cold 1 N NaOH and then 750 µl ice cold concentrated aqueous ammonia
(25 % w/w) was added stepwise until pH was 7.48 and a clear solution was obtained. Finally,
30 water was added to a total volume of 200 ml. The concentration of insulin aspart was 80 mg/ml.

Solution C2: 65 ml of solution C1 was diluted further to 130 ml. The concentration of
insulin aspart was 40 mg/ml.

35

Preparation D

Solution D1: 16 g insulin aspart was suspended in 150 ml water on an ice bath. Initially, 6.6 ml of ice cold 1 N NaOH and then 370 μ l ice cold concentrated aqueous ammonia (25 % w/w) was added stepwise until pH was 7.47 and a clear solution was obtained. Finally, water was added to a total volume of 200 ml. The concentration of insulin aspart was 80

5 mg/ml.

Solution D2: 65 ml of solution D1 was diluted further to 130 ml. The concentration of insulin aspart was 40 mg/ml.

Preparation E

10 Solution E1: 16 g insulin aspart was suspended in 150 ml water on an ice bath. Initially, 6.6 ml of ice cold 1 N NaOH and then 370 μ l ice cold concentrated aqueous ammonia (25 % w/w) was added stepwise until pH was 7.47 and a clear solution was obtained. Finally, water was added to a total volume of 200 ml. The concentration of insulin aspart was 80

mg/ml.

15 Solution E2: 65 ml of solution E1 was diluted further to 130 ml. The concentration of insulin aspart was 40 mg/ml.

Preparation F

20 1.8 g insulin aspart was suspended in 40 ml water on an ice bath. Initially, 175 μ l ice cold concentrated aqueous ammonia (25 % w/w) was added stepwise until pH was 7.83.

1.1 ml of a 0.1 M $ZnCl_2$ solution and 3.6 ml of a 0.32 M phenol solution was further added to the solution.

Finally, pH was adjusted to 7.99 with 85 μ l of diluted aqueous ammonia (8 % w/w) and water was added to a total volume of 60 ml. The solution was clear and the concentration of insulin aspart was 30 mg/ml.

Preparation G

30 1.8 g insulin aspart was suspended in 40 ml water on an ice bath. Initially, 288 μ l of ice cold 1 N NaOH and then 120 μ l ice cold concentrated aqueous ammonia (25 % w/w) was added stepwise until pH was 7.86.

1.1 ml of a 0.1 M $ZnCl_2$ solution and 3.6 ml of a 0.32 M phenol solution was further added to the solution.

Finally, pH was adjusted to 8.03 with 80 μ l of diluted aqueous ammonia (8 % w/w) and water was added to a total volume of 60 ml. The solution was clear and the concentration of insulin aspart was 30 mg/ml.

35

Preparation H

1.8 g insulin aspart was suspended in 40 ml water on an ice bath. Initially, 864 µl of ice cold 1 N NaOH and then 50 µl ice cold concentrated aqueous ammonia (25 % w/w) was added stepwise until pH was 7.85.

1.1 ml of a 0.1 M ZnCl₂ solution and 3.6 ml of a 0.32 M phenol solution was further added to the solution.

Finally, pH was adjusted to 7.98 with 60 µl of diluted aqueous ammonia (8 % w/w) and water was added to a total volume of 60 ml. The solution was clear and the concentration of insulin aspart was 30 mg/ml.

Preparation I

1.8 g insulin aspart was suspended in 40 ml water on an ice bath. Initially, 150 µl ice cold concentrated aqueous ammonia (25 % w/w) was added stepwise until pH was 7.99.

4.6 ml of a 0.25 M glycylglycine solution, 1.1 ml of a 0.1 M ZnCl₂ solution and 3.6 ml of a 0.32 M phenol solution was further added to the solution.

Finally, pH was adjusted to 7.98 with 245 µl of diluted aqueous ammonia (8 % w/w) and water was added to a total volume of 60 ml. The solution was clear and the concentration of insulin aspart was 30 mg/ml.

Preparation J

1.8 g insulin aspart was suspended in 40 ml water on an ice bath. Initially, 288 µl of ice cold 1 N NaOH and then 125 µl ice cold concentrated aqueous ammonia (25 % w/w) was added stepwise until pH was 8.18.

4.6 ml of a 0.25 M glycylglycine solution, 1.1 ml of a 0.1 M ZnCl₂ solution and 3.6 ml of a 0.32 M phenol solution was further added to the solution.

Finally, pH was adjusted to 7.98 with 125 µl of diluted aqueous ammonia (8 % w/w) and water was added to a total volume of 60 ml. The solution was clear and the concentration of insulin aspart was 30 mg/ml.

Preparation K

1.8 g insulin aspart was suspended in 40 ml water on an ice bath. Initially, 288 µl of ice cold 1 N NaOH and then 125 µl ice cold concentrated aqueous ammonia (25 % w/w) was added stepwise until pH was 7.93.

1.1 ml of a 0.1 M ZnCl₂ solution and 1.9 ml of a 0.32 M phenol solution was further added to the solution.

Finally, pH was adjusted to 7.98 with 40 µl of diluted aqueous ammonia (8 % w/w) and water was added to a total volume of 60 ml. The solution was clear and the concentration of insulin aspart was 30 mg/ml.

Dry, solid microparticles were prepared on a Büchi B-290 mini spray dryer (Büchi, Labortechnik AG Flawil, Switzerland) equipped with a 0.7 mm co-current two-fluid nozzle. The liquid feed (preparation A1, A2, B1, B2, C1, C2, D1, D2, E1, E2, F, G, H, I, J, and K) was atomised into hot air stream in a drying chamber at a liquid feed rate of 2 ml/min and at an atomising air flow of 600-800 liter/hour.

The drying air had an inlet temperature of 150°C and a drying air flow rate of 35 m³/hour. The outlet temperature varied between 41 and 61°C.

Solid microparticles were captured by a cyclone connected to the drying chamber and then gathered and stored at dry conditions.

Insulin chemical instability was studied by HPLC analysis as described in Hvass, 2003, (A. Hvass, M. Hach, and M. U. Jars. Complementary analytical HPLC methods for insulin-related degradation products. American Biotechnology Laboratory 21 (2): 8-12, 2003) following storage for 1 month at 40°C. Covalent-bound dimer and high molecular weight polymers (HMWP) were analysed size exclusion (SE) chromatography. Reverse-phase (RP) chromatography (pH 3.6) with gradient elution was used in the separation of degradation products (desamido forms of insulin and other insulin related impurities).

Moisture content of the dry microparticles was determined by loss on drying at 110°C for minimum 3 hours using a PerkinElmer Pyris TGA1 thermogravimetric analyzer. The weight change caused by moisture loss was registered and expressed in percent by weight.

An Aerodynamic Particle Sizer® spectrometer (APS) was used to determine particle size distribution (mass median aerodynamic diameter).

pH of the spray dried insulin was measured by dissolving the spray dried powders in demineralised water to a concentration of approximately 40 mg/ml and measuring pH by a potentiometer (Radiometer, Denmark).

The results from characterisation of the spray dried preparations A-K is listed in Table 1.

Table 1. Spray dried insulin aspart powders

Preparation ID	Moisture (%)	Solution pH	pH of the spray dried insulin	MMAD ^{A)} (µm)	Insulin aspart related impurities ^{B)} (%)	HMWP ^{C)} (%)
A1	5.6	7.5	5.35	2.7	1.1	0.43
A2	6.6	7.5	6.03	3.3	1.4	0.45
B1	6.3	7.5	6.04	3.0	1.1	2.17
B2	7.0	7.5	6.17	4.8	1.3	0.75
C1	6.7	7.5	6.27	3.3	0.8	0.63
C2	7.1	7.5	6.44	4.0	1.4	0.67
D1	5.9	7.5	6.66	3.3	0.3	0.26
D2	5.8	7.5	6.89	3.9	1.0	2.87
E1	6.6	7.5	7.43	3.2	0.4	0.22
E2	5.2	7.5	7.43	3.9	0.7	0.31
F	6.9	8.0	4.91	2.6	2.0	0.35
G	9.3	8.0	5.16	2.6	1.9	0.51
H	9.6	8.0	6.33	2.8	1.4	0.35
I	7.2	8.0	5.04	2.7	2.3	0.30
J	8.2	8.0	5.79	2.8	1.9	0.24
K	8.9	8.0	5.37	2.7	1.8	0.47

A) MMAD is the mass median aerodynamic diameter determined by APS

B) Insulin aspart related impurities formed following storage for 1 month at 40°C, measured by RP-HPLC (including desamido and other degradation forms of insulin aspart)

C) High molecular weight polymers formed following storage for 1 month at 40°C, measured by SE-HPLC

EXAMPLE 4

Spray drying of insulin aspart

361.8 g insulin aspart was dispersed in 4.5 liter ice cold demineralised water. The pH was adjusted to 7.68 with ice cold 0.2 NaOH. Water was added up to 9 liter. The final concentration of insulin aspart was 37 g/l. The solution was filtered through a sterile filter (0.2 µm) before spray drying.

Spray drying of the insulin aspart solution was performed on pilot scale spray dryer (model Mobile Minor, Niro, Denmark) with a two-fluid nozzle with a 1.0 mm orifice diameter. Nitrogen was used both as drying gas and as atomisation gas.

The inlet and outlet temperatures were 110 and 62°C, respectively. The feed flow was approximately 1 kg/h and the gas/feed ratio was approximately 11.

The spray dryer was equipped with both a cyclone and bag filters. The powder was collected simultaneously from both the cyclone and the bag filters during spray drying.

- 5 Particle size distribution was analysed by both laser diffraction (Mastersizer, Malvern) and aerodynamic particles sizing spectroscopy (APS). The chemical integrity of spray dried insulin aspart following storage at 1 month at 40°C was studied by SE og RP-HPLC as described in example 2.

	Cyclone fraction	Bag filter fraction
D50 ^{A)} (µm)	4.2	2.5
MMAD ^{B)} (µm)	3.5	2.1
Yield (%)	78	23
HMWP formed per month at 40°C (%)	0.2	0.4
Insulin related impurities formed per month at 40°C (%)	0.8	1.3

A) D50 is the volume median diameter determined by laser diffraction

B) MMAD is the mass median aerodynamic diameter determined by APS

EXAMPLE 5

Storage stability of freeze dried insulin aspart dry powders with various pH values

0.806 g of insulin aspart was dispersed in 10 ml ice cold water. The suspension was placed on ice bath and the initial pH was measured to pH 4.58. The pH was adjusted to 7.39 with ice cold 0.2 N sodium hydroxide, hereby solubilising the insulin aspart. Demineralised water was added to a total weight of 20.4 g.

The solubilised insulin aspart was divided into 6 aliquots of 2.5 ml, which were adjusted to pH 7.0, 7.7, 8.0, 8.5, 9.0 and 9.5 respectively. Demineralised water was added to a total weight of 3.06 g.

The insulin aspart solutions were freeze-dried in a Christ Alpha 2–4 LSC (Christ Alpha, Germany) apparatus in aliquots of 0.9 ml in glass vials using a standard freeze drying program.

pH of the freeze dried insulin aspart powders were measured by adding 0.5 ml of demineralised water to approximately 33 mg of insulin aspart powder and then measuring pH with a potentiometer equipped with a pH electrode after 15 minutes.

The chemical integrity of spray dried insulin aspart following dry (above silica gel) storage for 2 weeks at 40°C relative to controls at -18°C was studied by SE-HPLC as described in example 2.

Table 3. Freeze dried insulin aspart powders

Solution pH	pH of the freeze dried insulin	HMWP ^{A)} (%)
7.0	6.69	0.20
7.7	7.58	0.17
8.0	7.83	0.11
8.5	8.42	0.07
9.0	8.81	0.10
9.5	9.27	0.10

A) High molecular weight dimers and polymers formed following storage for 2 weeks at 40°C, measured by SE-HPLC

EXAMPLE 6

Storage stability of spray dried insulin aspart dry powders with various pH values

20.6 g of insulin aspart was dispersed in 300 ml ice cold water. The suspension was
5 placed on ice bath and the initial pH was measured to pH 4.63. The pH was adjusted to 7.50
with 100 ml of ice cold 0.1 N sodium hydroxide, hereby solubilising the insulin aspart.

The solubilised insulin aspart was divided into 6 aliquots 65 g, which were adjusted
to pH 7.0, 7.7, 8.0, 8.5, 9.0 and 9.5 respectively with ice cold 0.1 N NaOH. Demineralised
10 water was added to each aliquot to a total weight of 80.0 g. The concentration of insulin as-
part was approximately 38 mg/ml.

Dry, solid microparticles were prepared on a Büchi B-290 mini spray dryer (Büchi,
Labortechnik AG Flawil, Switzerland) equipped with a 0.7 mm co-current two-fluid nozzle.
The liquid feed (80 ml) was atomised into hot air stream in a drying chamber at a liquid feed
rate of 2 ml/min and at an atomising air flow of 600-800 liter/hour.

15 The drying air had an inlet temperature of 150°C and a drying air flow rate of 35
m³/hour. The outlet temperature varied between 49 and 61°C. Solid microparticles were cap-
tured by a cyclone connected to the drying chamber and then gathered and stored at dry
conditions.

pH of the spray dried insulin aspart was measured by dissolving the spray dried
20 powders in demineralised water to a concentration of 70-80 mg/ml and measuring pH by a
potentiometer (Radiometer, Denmark).

The chemical integrity of spray dried insulin aspart following dry (above silica gel)
storage for 4 weeks at 40°C relative to controls at -18°C was studied by SE-HPLC and RP-
HPLC as described in example 2.

25

Table 3. Stability of spray dried insulin aspart powders

Solution pH	pH of the spray dried insulin as- part	HMWP ^{A)} (%)	Purity ^{B)} (%)
7.5	7.28	0.28	98.2
7.7	7.54	0.26	98.3
8.0	7.82	0.22	98.3
8.5	8.26	0.19	98.4
9.0	8.58	0.23	98.2
9.5	9.00	1.34	95.0

- A) High molecular weight dimers and polymers formed following storage for 4 weeks at 40°C, measured by SE-HPLC
- B) Purity of spray dried insulin aspart following storage for 4 weeks at 40°C, measured by RP-HPLC

5

Example 7

20000 nmol of a lysine-acylated GLP1 analogue N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-Carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37) was dissolved in water to 4000 nmol/mL (molecular weight 4113 g/mol). 2 mL of the solution was adjusted to pH 7.6 by sodium hydroxide and further divided in 2 parts of which one was added ammonia (25 % in water) to pH 9.6. Similarly 2 mL solution was added sodium hydroxide to pH 8.7, divided in 2 parts and one added ammonia (25 % in water) to pH 10.3. Finally 1 mL GLP1 analogues solution was added sodium hydroxide to pH 10.3. The 5 samples were all freeze dried and redissolved to 40 mg/mL. pH values were measured in the samples to respectively 7.5, 7.5, 8.6, 8.6 and 9.7.

10

15

EXAMPLE 8

Spray drying of a GLP-1 analogue with volatile base

20

180 mg (43800 nmol) of a lysine-acylated GLP1 analogue N-epsilon26-[2-(2-{2-[2-(2-{2-[(S)-4-Carboxy-4-(17-carboxyheptadecanoylamino)butyrylamino]ethoxy}ethoxy)acetyl][Aib8,Arg34]GLP-1-(7-37) was dissolved in 7 ml of demineralised water and pH was adjusted from pH 7.53 to pH 7.03 with 0.2 N hydrochloric acid. Then the solution was adjusted to pH 9.96 with 0.25 % w/w aqueous ammonia and demineralised water was added to give a final concentration of GLP-1 analogue of 20 mg/ml.

25

The solution was atomised into hot air stream in a drying chamber of a Büchi B-290 mini spray dryer (Büchi, Labortechnik AG Flawil, Switzerland) equipped with a 0.7 mm co-current two-fluid nozzle at a liquid feed rate of 2 ml/min and at an atomising air flow of 600-800 liter/hour. The drying air had an inlet temperature of 150°C and a drying air flow rate of 35 m³/hour. The outlet temperature was approximately 63°C. Solid microparticles were captured by a cyclone connected to the drying chamber.

30

The powder was redissolved in demineralised water to 120 mg/ml and pH was measured to pH 6.9.

35

Example 9

Chemical instability of insulin aspart at strongly alkaline pH values

5 720 mg of insulin aspart was solubilized in 9 ml of demineralised water. 2.25 ml of the solution was adjusted from pH 7.6 to pH 10.0 with a 2 N ammonium hydroxide solution. Another 2.25 ml of the solution is adjusted to pH 11.0 with a 2 N ammonium hydroxide solution. Yet another 2.25 ml of the solution was adjusted to pH 12.0 with a 2 N ammonium hydroxide solution and a 1 N sodium hydroxide solution. And finally 2.25 ml of the solution was
10 adjusted to pH 12.6 with a 2 N ammonium hydroxide solution and a 1 N sodium hydroxide solution.

The four pH adjusted solutions were kept in the refrigerator at 3-8°C for 24 hours after which the four solutions were adjusted to neutral pH with 1 N hydrochloric acid in order to
15 quench the chemical degradation.

Insulin chemical instability in the neutralised solutions was studied by size exclusion and reverse phase HPLC analysis as described in example 2.

Table 4 . Chemical stability of insulin aspart solutions at various pH values

Solution pH	HMWP ^{A)} (%)	Purity ^{B)} (%)
7.6	0.0	97.2
10.0	0.5	97.8
11.0	1.8	92.2
12.0	49.8	7.8
12.6	39.5	2.3

20 A) High molecular weight dimers and polymers formed following storage for 24 hours at 3-8°C, measured by SE-HPLC

B) Purity of insulin aspart following storage for 24 hours at 3-8°C, measured by RP-HPLC

CLAIMS

1. A process for drying a protein solution, wherein
 - a) a protein solution is obtained by mixing a protein with water optionally comprising excipients and adjusting the pH with a volatile base, a non volatile base and optionally a non volatile acid for the protein solution to become alkaline, and
 - b) drying the protein solution
2. A process according to claim 1 comprising:
 - a) Selecting a target pH for the dried protein,
 - b) Selecting a target pH for the protein solution,
 - c) Providing an aqueous phase,
 - d) Adding a protein,
 - e) Optionally adding excipients,
 - f) Adjusting the pH with a non volatile base and optionally a non volatile acid to the target pH for the dried protein,
 - g) Adjusting the pH with a volatile base to the target pH of the protein solution to be dried, and
 - h) Spray-drying the protein solution.wherein the steps d, e, f and g can be carried out in any order while stirring continuously.
3. The process according to claims 1-2, wherein the protein solution is obtained at a temperature below 8°C.
4. The process according to claims 1-3, wherein the protein solution has a pH between 7.4 and 11.0.
5. The process according to claims 1-4, wherein the volatile base adjusts the pH of the protein solution with at least 0.5 pH unit.
6. The process according to claims 1-5, wherein the protein is selected from the group consisting of insulin, insulin analogues, insulin derivatives, GLP-1, GLP-1 analogues and GLP-1 derivatives, glucagon and/or any combination thereof.

7. The process according to claims 1-6, wherein the protein solution comprises a buffer, a detergent, a stabilizer, a protease inhibitor, a flavour, a carrier, an absorption protecting agent, a bulking agent or an agent improving the flowing properties or a penetration enhancer or a combination hereof

5

8. The process according to claims 1-7, wherein the protein solution comprises glycylglycine and/or phenol.

10

9. The process according to claims 1-8, wherein the protein solution comprises about 4 moles of phenol per mole of protein.

10. The process according to claims 1-9, wherein the pH of the protein solution is above the pH of the dried protein.

15

11. The process according to claims 1-10, wherein the drying method is selected from the group consisting of spray drying, spray freeze drying, fluid bed drying, freeze drying and vacuum drying.

12. Dried protein obtainable by the process of claims 1-11.

20

13. Pharmaceutical composition comprising a therapeutically effective amount of a dried protein according to claim 12.

25

14. Pharmaceutical composition according to claim 13 wherein the composition is for pulmonary, parenteral, nasal or oral treatment of diabetes or hyperglycaemia.

15. A method of treating diabetes in a patient in need of such a treatment, comprising administering to the patient a therapeutically effective amount of a dried protein according to any of the claim 11 or a pharmaceutical composition according to claims 13-14.

30

16. Dried protein as described in the examples.

35